Esperion Therapeutics, Inc. (ESPR)

$6.45

+0.09 (+1.42%)
Rating:
Recommendation:
Neutral
Symbol ESPR
Price $6.45
Beta 0.424
Volume Avg. 1.23M
Market Cap 415.243M
Shares () -
52 Week Range 3.28-21.55
1y Target Est -
DCF Unlevered ESPR DCF ->
DCF Levered ESPR LDCF ->
ROE 84.42% Strong Buy
ROA -68.51% Strong Sell
Operating Margin -
Debt / Equity -237.67% Sell
P/E -
P/B -1.58 Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ESPR news


Mr. Timothy Mayleben
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Global Market

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.